Named Bioactive Compounds · Compound
Neobavaisoflavone
Moderate Evidencecompound2 PubMed Studies
Hermetica Superfood Encyclopedia
Neobavaisoflavone is an isoflavonoid compound found in Psoralea corylifolia that demonstrates antioxidant and anti-inflammatory properties. It works primarily through the SPLET mechanism to neutralize free radicals and inhibits pro-inflammatory cytokine production.
Neobavaisoflavone is a prenylated isoflavone (C₂₀H₁₈O₄) primarily isolated from the seeds of Psoralea corylifolia L., a plant used in traditional medicine systems. This naturally occurring compound features a flavonoid backbone with a prenyl group at position 3' and hydroxyl groups at positions 7 and 4'.
The available research consists primarily of in vitro and computational studies rather than human clinical trials. A 2023 computational study published in New Journal of Chemistry examined the compound's antioxidant properties, but no human RCTs or meta-analyses with PubMed PMIDs were found in the provided research.
No clinically studied dosage ranges for human use are available in the research. Commercial suppliers offer research-grade neobavaisoflavone at ≥98% purity dissolved in organic solvents, but human dosing protocols have not been established. Consult a healthcare provider before starting any new supplement.
Neobavaisoflavone is a prenylated isoflavonoid (chemical formula: C₂₀H₁₈O₄; molecular weight: 322.36 g/mol) and is not a nutritional food source but rather a bioactive phytochemical. It is found in trace quantities in specific medicinal plants, primarily Psoralea corylifolia (Babchi) seeds, as well as in certain Erythrina and Dalbergia species. Typical concentrations in Psoralea corylifolia seed extracts range from approximately 0.1–1.5% w/w depending on extraction method and plant part. As an isolated compound, it contains no meaningful macronutrients (protein, carbohydrates, fats, fiber) or micronutrients (vitamins, minerals). Key structural features include a 4'-hydroxyl group on the isoflavone backbone and a 3,3-dimethylallyl (prenyl) side chain at the C-8 position, which enhances lipophilicity compared to non-prenylated isoflavones. The prenyl group contributes to improved membrane permeability and potentially greater oral bioavailability relative to simple isoflavones such as daidzein or genistein, though specific human pharmacokinetic data remain limited. In vitro studies suggest moderate lipophilicity (estimated LogP ~4.0–4.5), indicating preferential absorption through lipid-based pathways. Bioavailability may be limited by Phase II hepatic metabolism (glucuronidation and sulfation), similar to other isoflavonoids. No established dietary reference intake or recommended dosage exists for humans. Concentrations used in in vitro studies typically range from 1–50 μM. The compound is generally encountered as a minor secondary metabolite within whole-plant extracts rather than as a standalone dietary nutrient.
Neobavaisoflavone operates through the Sequential Proton Loss Electron Transfer (SPLET) mechanism to effectively scavenge peroxyl radicals and nitrogen dioxide radicals. The compound inhibits the production of key pro-inflammatory cytokines including interleukin-1β (IL-1β), interleukin-6 (IL-6), IL-12p40, and IL-12p70. This dual antioxidant-anti-inflammatory action suggests modulation of NF-κB and other inflammatory signaling cascades.
Current evidence for neobavaisoflavone is limited to computational and in vitro studies conducted in 2023. These preliminary investigations demonstrate radical scavenging activity and cytokine inhibition in laboratory settings. No human clinical trials, animal studies with dosage parameters, or safety data are currently available in peer-reviewed literature. The evidence remains at the preclinical stage and requires substantial research before therapeutic applications can be established.
No safety data, side effect profiles, or drug interaction studies exist for neobavaisoflavone as an isolated compound. Safety during pregnancy, breastfeeding, or in pediatric populations has not been established. Potential interactions with anticoagulant medications, immunosuppressive drugs, or other supplements remain unknown. Given the lack of human studies, dosage guidelines and contraindications have not been determined.
